FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304037> ?p ?o ?g. }

• W4367304037 abstract "<h3>Objective:</h3> To assess weekly patterns in migraine-related healthcare resource use (HCRU) and acute medication use, as proxy for wearing-off with fremanezumab, in US adult migraine patients. <h3>Background:</h3> Wearing-off is the phenomenon whereby clinical symptoms return/worsen before the next scheduled treatment dose. Post-hoc data showed no evidence of wearing-off with monthly and quarterly dose fremanezumab; no respective real-world data are available. <h3>Design/Methods:</h3> This retrospective, observational US claims database analysis included adult migraine patients with ≥2 fremanezumab claims in monthly treatment cycles. The proportions of patients with ≥1 migraine-related HCRU (inpatient, emergency room, outpatient visit or ≥1 migraine-related acute medication claim were descriptively assessed at Weeks 1, 2, 3, and 4 of Cycles 1, 3, 6, and 12. Confidence intervals (CI) at 95% were calculated; overlapping CIs indicated no statistically significant trends in the week-to-week outcome values within each cycle, indicating no wearing-off. Sensitivity analysis examined weekly HCRU and acute medication use during the first 24 cycles. <h3>Results:</h3> During all assessed monthly dosing cycles (N=3217), there were no significant trends indicating wearing-off in migraine-related HCRU or acute medication use. In Cycle 1, the 95% CIs for patients with ≥1 migraine-related outpatient visit at Weeks 1, 2, 3, and 4 overlapped: [5.41%, 7.28%], [4.56%, 6.29%], [5.38%, 7.24%] and [4.93%, 6.73%] respectively. Similarly, 95% CIs for patients with ≥1 migraine-related triptan use were [5.14%, 6.97%], [4.69%, 6.45%], [4.56%, 6.29%] and [5.72%, 7.64%]. Similar trends were observed across Cycles 3, 6, and 12 for all outcomes. Notably, outpatient visits decreased during Cycle 3. Sensitivity analysis confirmed there were no significant trends in outcome values across Cycles 1–24. Quarterly dosing results showed similar trends. <h3>Conclusions:</h3> Over monthly dosing cycles of fremanezumab, no increases in migraine-related HCRU and acute medication use were seen, representing no evidence of wearing-off with fremanezumab and confirming post-hoc findings. <b>Disclosure:</b> Dr. Ailani has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Allergan/Abbvie. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Ailani has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck/Alder. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Impel. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nesos. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GlaxoSmithKline. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BiodeliveryScienceIndustry. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Miravo. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Impel. Dr. Ailani has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Satsuma. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axsome. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lindpharma. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Report. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Live. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medscape. Dr. Ailani has stock in Ctrl M. The institution of Dr. Ailani has received research support from Allergan/Abbvie. The institution of Dr. Ailani has received research support from Eli Lilly. The institution of Dr. Ailani has received research support from Zosano. Dr. Ailani has received research support from Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Advisory Panel with Medscape. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Medical Advisor with SELF. Mr. XIE has received personal compensation for serving as an employee of TEVA Pharmaceutical. Maurice Driessen has received personal compensation for serving as an employee of Teva Pharmaceuticals. Mario Ortega has received personal compensation for serving as an employee of Teva Pharmaceuticals. Ms. Wang has nothing to disclose. Dr. Ramirez Campos has received personal compensation for serving as an employee of Teva Pharmaceuticals. Mr. Lim has received personal compensation for serving as an employee of Teva Pharmaceuticals. Mr. Lim has stock in Teva Pharmaceuticals." @default.
• W4367304037 created "2023-04-29" @default.
• W4367304037 creator A5013831985 @default.
• W4367304037 creator A5024982238 @default.
• W4367304037 creator A5048130857 @default.
• W4367304037 creator A5057037500 @default.
• W4367304037 creator A5064317006 @default.
• W4367304037 creator A5066996120 @default.
• W4367304037 creator A5071868650 @default.
• W4367304037 date "2023-04-25" @default.
• W4367304037 modified "2023-10-14" @default.
• W4367304037 title "No ‘Wearing-Off Effect’ Seen with Fremanezumab in the Real-World: Retrospective, Claims-Based Analysis of Migraine-Related Healthcare Resource and Acute Medication Use (P12-12.005)" @default.
• W4367304037 doi "https://doi.org/10.1212/wnl.0000000000203473" @default.
• W4367304037 hasPublicationYear "2023" @default.
• W4367304037 type Work @default.
• W4367304037 citedByCount "0" @default.
• W4367304037 crossrefType "proceedings-article" @default.
• W4367304037 hasAuthorship W4367304037A5013831985 @default.
• W4367304037 hasAuthorship W4367304037A5024982238 @default.
• W4367304037 hasAuthorship W4367304037A5048130857 @default.
• W4367304037 hasAuthorship W4367304037A5057037500 @default.
• W4367304037 hasAuthorship W4367304037A5064317006 @default.
• W4367304037 hasAuthorship W4367304037A5066996120 @default.
• W4367304037 hasAuthorship W4367304037A5071868650 @default.
• W4367304037 hasConcept C126322002 @default.
• W4367304037 hasConcept C160735492 @default.
• W4367304037 hasConcept C162324750 @default.
• W4367304037 hasConcept C167135981 @default.
• W4367304037 hasConcept C187212893 @default.
• W4367304037 hasConcept C194828623 @default.
• W4367304037 hasConcept C23131810 @default.
• W4367304037 hasConcept C2777288759 @default.
• W4367304037 hasConcept C2778541695 @default.
• W4367304037 hasConcept C2780564907 @default.
• W4367304037 hasConcept C44249647 @default.
• W4367304037 hasConcept C50522688 @default.
• W4367304037 hasConcept C71924100 @default.
• W4367304037 hasConceptScore W4367304037C126322002 @default.
• W4367304037 hasConceptScore W4367304037C160735492 @default.
• W4367304037 hasConceptScore W4367304037C162324750 @default.
• W4367304037 hasConceptScore W4367304037C167135981 @default.
• W4367304037 hasConceptScore W4367304037C187212893 @default.
• W4367304037 hasConceptScore W4367304037C194828623 @default.
• W4367304037 hasConceptScore W4367304037C23131810 @default.
• W4367304037 hasConceptScore W4367304037C2777288759 @default.
• W4367304037 hasConceptScore W4367304037C2778541695 @default.
• W4367304037 hasConceptScore W4367304037C2780564907 @default.
• W4367304037 hasConceptScore W4367304037C44249647 @default.
• W4367304037 hasConceptScore W4367304037C50522688 @default.
• W4367304037 hasConceptScore W4367304037C71924100 @default.
• W4367304037 hasLocation W43673040371 @default.
• W4367304037 hasOpenAccess W4367304037 @default.
• W4367304037 hasPrimaryLocation W43673040371 @default.
• W4367304037 hasRelatedWork W2078986510 @default.
• W4367304037 hasRelatedWork W2136373160 @default.
• W4367304037 hasRelatedWork W2152831326 @default.
• W4367304037 hasRelatedWork W2411067084 @default.
• W4367304037 hasRelatedWork W2917552688 @default.
• W4367304037 hasRelatedWork W2937991864 @default.
• W4367304037 hasRelatedWork W3081102954 @default.
• W4367304037 hasRelatedWork W3091031626 @default.
• W4367304037 hasRelatedWork W3129544543 @default.
• W4367304037 hasRelatedWork W3172467076 @default.
• W4367304037 isParatext "false" @default.
• W4367304037 isRetracted "false" @default.
• W4367304037 workType "article" @default.